Why Array BioPharma Skyrocketed 91% in September


Image source: Getty Images.

After reporting that the FDA has accepted its application for approval of binimetinib and delivering positive trial results from a study of binimetinib and encorafenib combination therapy, shares in Array BioPharma (NASDAQ: ARRY) soared 91.8% last month, according to S&P Global Market Intelligence.

Continue reading

посмотреть на Fool